PA8569701A1 - Hidrato estable de un antagonista de receptores muscarinicos - Google Patents

Hidrato estable de un antagonista de receptores muscarinicos

Info

Publication number
PA8569701A1
PA8569701A1 PA20038569701A PA8569701A PA8569701A1 PA 8569701 A1 PA8569701 A1 PA 8569701A1 PA 20038569701 A PA20038569701 A PA 20038569701A PA 8569701 A PA8569701 A PA 8569701A PA 8569701 A1 PA8569701 A1 PA 8569701A1
Authority
PA
Panama
Prior art keywords
synthro
urbanity
bladder
treatment
antagonist
Prior art date
Application number
PA20038569701A
Other languages
English (en)
Inventor
Peter James Dunn
John George Matthews
Trevor Jack Newbury
Gary O'connor
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8569701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PA8569701A1 publication Critical patent/PA8569701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UN HIDRATO SOLIDO ESTABLE DE UN ANTAGONISTA DE RECEPTORES MUSCARINICOS ES UTIL EN EL TRATAMIENTO DE SINDROME DE INTESTINO IRRITABLE, ENFERMEDAD DIVERTICULAR, ACALASIA ESOFAGICA, ENFERMEDAD OBSTRUCTIVA CRONICA DE LAS VIAS RESPIRATORIAS, VEJIGA HIPERACTIVA (QUE INCLUYE LOS SINTOMAS DE INCONTINENCIA, URGENCIA Y FRECUENCIA), INCONTINENCIA URINARIA, URGENCIA URINARIA NEUROGENICA O POLAQUIURIA, TRATAMIENTO DEL TRASTORNO FUNCIONAL DE LA VEJIGA, PERDIDA DE ORINA, DOLOR O DIFICULTAD DE LA MICCION CAUSADA POR LA VEJIGA NEUROGENICA, VEJIGA ESPASTICA O HIPERTONICA, SINDROME DE VEJIGA DISFUNCIONAL, TRASTORNOS GASTROINTESTINALES QUE INCLUYEN HIPERACTIVIDAD GASTROINTESTINAL, Y EFECTO RELAJANTE EN LAS CELULAS DEL MUSCULO LISO INTESTINAL.
PA20038569701A 2002-03-26 2003-03-20 Hidrato estable de un antagonista de receptores muscarinicos PA8569701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0207104.1A GB0207104D0 (en) 2002-03-26 2002-03-26 Stable hydrate of a muscarinic receptor antagonist

Publications (1)

Publication Number Publication Date
PA8569701A1 true PA8569701A1 (es) 2003-12-10

Family

ID=9933731

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038569701A PA8569701A1 (es) 2002-03-26 2003-03-20 Hidrato estable de un antagonista de receptores muscarinicos

Country Status (23)

Country Link
US (3) US6930188B2 (es)
EP (2) EP1490357B1 (es)
JP (2) JP2005524678A (es)
KR (4) KR20120098888A (es)
CN (1) CN100345840C (es)
AR (1) AR042608A1 (es)
AT (1) ATE495169T1 (es)
AU (1) AU2003209921A1 (es)
BR (2) BRPI0308706B8 (es)
CA (1) CA2480287C (es)
CY (2) CY1111200T1 (es)
DE (1) DE60335711D1 (es)
DK (2) DK2336124T3 (es)
ES (2) ES2358644T3 (es)
GB (1) GB0207104D0 (es)
HK (2) HK1080847A1 (es)
PA (1) PA8569701A1 (es)
PT (2) PT1490357E (es)
SI (2) SI2336124T1 (es)
SV (1) SV2003001515A (es)
TW (1) TW200306816A (es)
UY (1) UY27735A1 (es)
WO (1) WO2003080599A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
AU2006239941A1 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
US20070197630A1 (en) * 2005-12-27 2007-08-23 Valeriano Merli Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
EP2109601A2 (en) * 2007-01-05 2009-10-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
RU2452728C2 (ru) * 2007-02-23 2012-06-10 Тереванс, Инк. Четвертичные аммониевые дифенилметилсоединения, применимые в качестве антагонистов мускариновых рецепторов
WO2008144602A1 (en) * 2007-05-18 2008-11-27 Auspex Pharmaceuticals, Inc. Deuterated zamifenacin derivatives
WO2009007853A2 (en) * 2007-06-08 2009-01-15 Actavis Group Ptc Ehf Novel polymorphs of darifenacin free base and its hydrobromide salt
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
AR068322A1 (es) * 2007-07-13 2009-11-11 Medichem Sa Forma amorfa de hidrobromuro de darifenacina y procedimientos para su preparacion
CZ200845A3 (cs) 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
EP2261205A4 (en) 2008-04-02 2012-06-06 Kaneka Corp PROCESS FOR PRODUCING (S) -3- (1-CYANO-1,1-DIPHENYLMETHYL) -PYRROLIDINE
WO2010032225A2 (en) * 2008-09-22 2010-03-25 Watson Pharma Private Limited Process for preparation of darifenacin and intermediates used in the process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
AU2016371762A1 (en) * 2015-12-14 2018-06-21 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
DK3497075T3 (da) * 2016-08-12 2020-08-31 Bayer Cropscience Ag Fremgangsmåde til fremstilling af substituerede styren-derivater

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
AU4421697A (en) * 1996-09-19 1998-04-14 American Home Products Corporation Method of treating urinary incontinence
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
US7696357B2 (en) 2010-04-13
US20050245597A1 (en) 2005-11-03
CY1113433T1 (el) 2016-06-22
BR0308706A (pt) 2005-01-04
CN1642945A (zh) 2005-07-20
HK1080847A1 (en) 2006-05-04
ES2394067T3 (es) 2013-01-16
CY1111200T1 (el) 2015-06-11
ES2358644T3 (es) 2011-05-12
SV2003001515A (es) 2003-12-15
ATE495169T1 (de) 2011-01-15
AU2003209921A1 (en) 2003-10-08
TW200306816A (en) 2003-12-01
UY27735A1 (es) 2003-10-31
CA2480287A1 (en) 2003-10-02
HK1156626A1 (en) 2012-06-15
KR20100101182A (ko) 2010-09-16
EP1490357A1 (en) 2004-12-29
US20030191176A1 (en) 2003-10-09
DE60335711D1 (de) 2011-02-24
AR042608A1 (es) 2005-06-29
KR101212908B1 (ko) 2012-12-14
SI2336124T1 (sl) 2012-12-31
JP2005524678A (ja) 2005-08-18
SI1490357T1 (sl) 2011-05-31
BRPI0308706B8 (pt) 2021-05-25
DK2336124T3 (da) 2012-12-17
BR122018000397B8 (pt) 2021-07-27
JP2010195828A (ja) 2010-09-09
KR20040093477A (ko) 2004-11-05
KR101026283B1 (ko) 2011-03-31
US20080167367A1 (en) 2008-07-10
EP2336124B1 (en) 2012-08-29
EP2336124A1 (en) 2011-06-22
KR20110130539A (ko) 2011-12-05
CN100345840C (zh) 2007-10-31
WO2003080599A1 (en) 2003-10-02
US6930188B2 (en) 2005-08-16
GB0207104D0 (en) 2002-05-08
BRPI0308706B1 (pt) 2018-07-10
PT2336124E (pt) 2012-12-12
KR20120098888A (ko) 2012-09-05
CA2480287C (en) 2011-05-31
PT1490357E (pt) 2011-03-01
DK1490357T3 (da) 2011-04-04
EP1490357B1 (en) 2011-01-12
BR122018000397B1 (pt) 2019-07-02

Similar Documents

Publication Publication Date Title
PA8569701A1 (es) Hidrato estable de un antagonista de receptores muscarinicos
WO2006050244A3 (en) Treatment of short bowel syndrome patients with colon-in-continuity
NO20054959D0 (no) Fremgangsmater for behandling av interleukin-6 relaterte sykdommer
EA200900796A1 (ru) Пиперидиновые агонисты gpcr
EA200900880A1 (ru) Пиперидиновые агонисты gpcr
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
DK1280531T3 (da) Formulering bestående af phentolaminmesylat og anvendelse heraf
AU2003273300A8 (en) Modified glp-1 receptor agonists and their pharmacological methods of use
NO20080052L (no) G-Protein kopplede reseptoragonister
NZ541928A (en) Remedy for spinal injury containing interleukin-6 antagonist
JP2009543825A5 (es)
EP1782830A4 (en) PREVENTION AND / OR REMEDY FOR LOWER URINARY TRACT DISEASES CONTAINING AN EP4 AGONIST
EP2535330A3 (en) Iminopyridine derivative and use thereof
Siracusa et al. Pelvic floor considerations in COVID-19
UY26627A1 (es) Antagonistas de receptores de il-8
DOP2003000615A (es) Hidrato estable de un antagonista de receptores muscarinicos
TR200103448T2 (tr) IL-8 reseptör antagonistleri.
DK1585546T3 (da) KIM- 1- Antagonister og Brug til at Modulere Immunsystem
ATE375146T1 (de) Schleimdrogenbasierte lutschtablette gegen entzündliche erkrankungen des mund- und rachenraums
DK1965800T3 (da) Piperidin-derivater til anvendelse i behandling af inkontinenser
BR0214998A (pt) Combinações farmacêuticas de agonistas do receptor da adenosina a-2a e do receptor adrenérgico beta-2
FR2845916B1 (fr) Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
UY27564A1 (es) Combinación farmacéutica.
Saito The syntax abilities of children and adolescents with Down syndrome
AR024349A1 (es) Antagonistas del receptor de il-8